September 12, 2016
1 min read
Save

ASH to present Henry M. Stratton Medal to two senior investigators

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ASH will present the Henry M. Stratton Medal to J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD.

The Henry M. Stratton Medal honors senior investigators whose contributions to basic and clinical/translational hematology research are well recognized and have taken place over a period of several years. Sadler and Tefferi will receive their awards during the ASH Annual Meeting and Exposition, which will be held in December in San Diego.

Evan J. Sadler
J. Evan Sadler

Sadler — professor of medicine, professor of biochemistry and molecular biophysics, and director of the hematology division at Washington University School of Medicine in St. Louis — is being recognized for his contributions in basic hematology research.

Sadler has pioneered the study of several blood coagulation factors. His research has made key contributions to the characterization of von Willebrand factor and ADAMTS13, two proteins associated with bleeding and clotting disorders.

Ayalew Tefferi
Ayalew Tefferi,

Tefferi —professor of medicine at Mayo Clinic College of Medicine in Rochester, Minnesota — is being recognized for his contributions in clinical/translational hematology research.

Tefferi is most known for his work that helped define the pathogenesis and prognostic features of myeloproliferative neoplasms, as well as tested novel treatments. He led the effort to discover and characterize pathogenic mutations in myeloproliferative neoplasms, which laid the foundation for clinical trials that assessed JAK inhibitors in this patient population.

Charles Abrams
Charles S. Abrams

“I am honored to present the Henry M. Stratton Medal to Drs. Sadler and Tefferi for their outstanding work and commitment in researching and treating human hemorrhagic and thrombotic disorders and myeloproliferative neoplasms, respectively,” ASH President Charles S. Abrams, MD, said in a press release. “Their important contributions to hematology are only matched by their selfless dedication to fostering the careers of others. They truly epitomize the best in leadership and service to our community.”